Cargando…

Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs

Cardiovascular diseases remain a major challenge for modern drug discovery. The diseases are chronic, complex, and the result of sophisticated interactions between genetics and environment involving multiple cell types and a host of systemic factors. The clinical events are often abrupt, and the dis...

Descripción completa

Detalles Bibliográficos
Autores principales: Kithcart, Aaron, MacRae, Calum A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113531/
https://www.ncbi.nlm.nih.gov/pubmed/30167552
http://dx.doi.org/10.1016/j.jacbts.2017.01.004
_version_ 1783351027786842112
author Kithcart, Aaron
MacRae, Calum A.
author_facet Kithcart, Aaron
MacRae, Calum A.
author_sort Kithcart, Aaron
collection PubMed
description Cardiovascular diseases remain a major challenge for modern drug discovery. The diseases are chronic, complex, and the result of sophisticated interactions between genetics and environment involving multiple cell types and a host of systemic factors. The clinical events are often abrupt, and the diseases may be asymptomatic until a highly morbid event. Target selection is often based on limited information, and though highly specific agents are often identified in screening, their final efficacy is often compromised by unanticipated systemic responses, a narrow therapeutic index, or substantial toxicities. Our understanding of complexity of cardiovascular disease has grown dramatically over the past 2 decades, and the range of potential disease mechanisms now includes pathways previously thought only tangentially involved in cardiac or vascular disease. Despite these insights, the majority of active cardiovascular agents derive from a remarkably small number of classes of agents and target a very limited number of pathways. These agents have often been used initially for particular indications and then discovered serendipitously to have efficacy in other cardiac disorders or in a manner unrelated to their original mechanism of action. In this review, the rationale for in vivo screening is described, and the utility of the zebrafish for this approach and for complementary work in functional genomics is discussed. Current limitations of the model in this setting and the need for careful validation in new disease areas are also described. An overview is provided of the complex mechanisms underlying most clinical cardiovascular diseases, and insight is offered into the limits of single downstream pathways as drug targets. The zebrafish is introduced as a model organism, in particular for cardiovascular biology. Potential approaches to overcoming the hurdles to drug discovery in the face of complex biology are discussed, including in vivo screening of zebrafish genetic disease models.
format Online
Article
Text
id pubmed-6113531
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-61135312018-08-30 Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs Kithcart, Aaron MacRae, Calum A. JACC Basic Transl Sci STATE-OF-THE-ART REVIEW Cardiovascular diseases remain a major challenge for modern drug discovery. The diseases are chronic, complex, and the result of sophisticated interactions between genetics and environment involving multiple cell types and a host of systemic factors. The clinical events are often abrupt, and the diseases may be asymptomatic until a highly morbid event. Target selection is often based on limited information, and though highly specific agents are often identified in screening, their final efficacy is often compromised by unanticipated systemic responses, a narrow therapeutic index, or substantial toxicities. Our understanding of complexity of cardiovascular disease has grown dramatically over the past 2 decades, and the range of potential disease mechanisms now includes pathways previously thought only tangentially involved in cardiac or vascular disease. Despite these insights, the majority of active cardiovascular agents derive from a remarkably small number of classes of agents and target a very limited number of pathways. These agents have often been used initially for particular indications and then discovered serendipitously to have efficacy in other cardiac disorders or in a manner unrelated to their original mechanism of action. In this review, the rationale for in vivo screening is described, and the utility of the zebrafish for this approach and for complementary work in functional genomics is discussed. Current limitations of the model in this setting and the need for careful validation in new disease areas are also described. An overview is provided of the complex mechanisms underlying most clinical cardiovascular diseases, and insight is offered into the limits of single downstream pathways as drug targets. The zebrafish is introduced as a model organism, in particular for cardiovascular biology. Potential approaches to overcoming the hurdles to drug discovery in the face of complex biology are discussed, including in vivo screening of zebrafish genetic disease models. Elsevier 2017-02-27 /pmc/articles/PMC6113531/ /pubmed/30167552 http://dx.doi.org/10.1016/j.jacbts.2017.01.004 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle STATE-OF-THE-ART REVIEW
Kithcart, Aaron
MacRae, Calum A.
Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
title Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
title_full Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
title_fullStr Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
title_full_unstemmed Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
title_short Using Zebrafish for High-Throughput Screening of Novel Cardiovascular Drugs
title_sort using zebrafish for high-throughput screening of novel cardiovascular drugs
topic STATE-OF-THE-ART REVIEW
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6113531/
https://www.ncbi.nlm.nih.gov/pubmed/30167552
http://dx.doi.org/10.1016/j.jacbts.2017.01.004
work_keys_str_mv AT kithcartaaron usingzebrafishforhighthroughputscreeningofnovelcardiovasculardrugs
AT macraecaluma usingzebrafishforhighthroughputscreeningofnovelcardiovasculardrugs